New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - levetiracetam 500mg;  ;   - film coated tablet - 500 mg - active: levetiracetam 500mg     excipient: colloidal silicon dioxide croscarmellose sodium macrogol 6000 magnesium stearate opadry yellow 85f32004 - use in epileptic patients aged 6 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 6 years of age with idiopathic generalized epilepsy (ige).

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - levetiracetam 750mg;  ;  ;  ;  ;   - film coated tablet - 750 mg - active: levetiracetam 750mg           excipient: colloidal silicon dioxide croscarmellose sodium macrogol 6000 magnesium stearate opadry orange 85f23452 - use in epileptic patients aged 6 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation. monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 6 years of age with idiopathic generalized epilepsy (ige).

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - rotigotine 4.5mg; rotigotine 4.5mg - transdermal patch - 2 mg/24h - active: rotigotine 4.5mg excipient: ascorbyl palmitate dl-alpha tocopherol silicone adhesive bio-psa q7-4301 silicone adhesive bio-psa q7-4201 povidone sodium metabisulfite active: rotigotine 4.5mg excipient: ascorbyl palmitate dl-alpha tocopherol silicone adhesive bio-psa q7-4301 silicone adhesive bio-psa q7-4201 povidone sodium metabisulfite - neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - rotigotine 9mg; rotigotine 9mg - transdermal patch - 4 mg/24h - active: rotigotine 9mg excipient: ascorbyl palmitate dl-alpha tocopherol silicone adhesive bio-psa q7-4301 silicone adhesive bio-psa q7-4201 povidone sodium metabisulfite active: rotigotine 9mg excipient: ascorbyl palmitate dl-alpha tocopherol silicone adhesive bio-psa q7-4301 silicone adhesive bio-psa q7-4201 povidone sodium metabisulfite - neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - rotigotine 13.5mg; rotigotine 13.5mg - transdermal patch - 6 mg/24h - active: rotigotine 13.5mg excipient: ascorbyl palmitate dl-alpha tocopherol silicone adhesive bio-psa q7-4301 silicone adhesive bio-psa q7-4201 povidone sodium metabisulfite active: rotigotine 13.5mg excipient: ascorbyl palmitate dl-alpha tocopherol silicone adhesive bio-psa q7-4301 silicone adhesive bio-psa q7-4201 povidone sodium metabisulfite - neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - rotigotine 18mg; rotigotine 18mg - transdermal patch - 8 mg/24h - active: rotigotine 18mg excipient: ascorbyl palmitate dl-alpha tocopherol silicone adhesive bio-psa q7-4301 silicone adhesive bio-psa q7-4201 povidone sodium metabisulfite active: rotigotine 18mg excipient: ascorbyl palmitate dl-alpha tocopherol silicone adhesive bio-psa q7-4301 silicone adhesive bio-psa q7-4201 povidone sodium metabisulfite - neupro is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic parkinson's disease from early stage to advanced disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - phleum pratense, quantity: 75000 sq-t - tablet - excipient ingredients: gelatin; mannitol; sodium hydroxide; purified water - grazax is indicated for disease modifying treatment of grass pollen (phleum pratense or allergens cross reacting with p. pratense) induced allergic rhinitis with or without conjunctivitis in adults, adolescents and children above the age of 5 years.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - diphtheria toxoid, adsorbed 2 [iu]; tetanus toxoid, adsorbed 20 [iu]; diphtheria toxoid, adsorbed 2 [iu]; tetanus toxoid, adsorbed 20 [iu] - solution for injection - active: diphtheria toxoid, adsorbed 2 [iu] tetanus toxoid, adsorbed 20 [iu] excipient: aluminium phosphate dibasic sodium phosphate dodecahydrate monobasic sodium phosphate dihydrate sodium chloride thiomersal water for injection active: diphtheria toxoid, adsorbed 2 [iu] tetanus toxoid, adsorbed 20 [iu] excipient: aluminium phosphate dibasic sodium phosphate dodecahydrate monobasic sodium phosphate dihydrate sodium chloride thiomersal water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - tuberculin purified protein derivative 100 iu/ml - solution for injection - 100 iu/ml - active: tuberculin purified protein derivative 100 iu/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - bacillus calmette-guerin - solution for injection - 1.7mg, 60mg - active: bacillus calmette-guerin excipient: sodium chloride